SCHEMBL407138

SCHEMBL407138

Cc1cc(O)n(-c2ccc(C)c(C)c2)n1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.48
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
PAX8 Q06710 1/20 0.48
STAT1 P42224 1/20 0.46
CYP1A2 P05177 3/20 0.45
CYP2C19 P33261 3/20 0.45
CA1 P00915 7/20 0.44
CA2 P00918 7/20 0.44
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11436903 0.81 MAPK1 (0.44) ALDH1A1KMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL11441588 0.81 CYP1A2 (0.47) ALDH1A1KMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL28620570 0.81 MAPK1 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL12918498 0.81 ALDH1A1 (0.66) ALDH1A1KMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL23398657 0.81 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL23398671 0.80 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL528347 0.79 RAB9A (0.69) ALDH1A1SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL31522193 0.79 ALDH1A1 (0.50) ALDH1A1LMNAHTTCYP1A2CYP2C19
SCHEMBL13902297 0.79 ALDH1A1 (0.50) ALDH1A1LMNAHTTCYP1A2CYP2C19
SCHEMBL200831 0.79 MAPK1 (0.63) ALDH1A1KMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3828159-A1 STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS BASF SE (DE) 2021-06-02 EP disclosed
US-10336706-B2 Crystalline form of Eltrombopag free acid HETERO RESEARCH FOUNDATION (IN) 2019-07-02 US disclosed
US-20170275255-A1 CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID HETERO RESEARCH FOUNDATION (IN) 2017-09-28 US disclosed
EP-3188737-A1 CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID Hetero Research Foundation (IN) 2017-07-12 EP disclosed
WO-2016035018-A1 CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID HETERO RESEARCH FOUNDATION (IN) 2016-03-10 WO disclosed
US-8372822-B2 Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof PLIVA HRVATSKA D.O.O. (HR) 2013-02-12 US disclosed
US-20120238612-A1 POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF PLIVA HRVATSKA D.O.O. (HR) 2012-09-20 US disclosed
US-8217021-B2 Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof PLIVA HRVATSKA D.O.O. (HR) 2012-07-10 US disclosed
US-8143287-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2012-03-27 US disclosed
US-8143287-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2012-03-27 US disclosed
US-7956048-B2 Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof PLIVA HRVATSKA D.O.O. (HR) 2011-06-07 US disclosed
US-20100323965-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2010-12-23 US disclosed
US-20100323965-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2010-12-23 US disclosed
WO-2010114943-A1 POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF PLIVA HRVATSKA D.O.O. (HR) 2010-10-07 WO disclosed
US-20100256212-A1 POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF PLIVA HRVATSKA D.O.O. (HR) 2010-10-07 US disclosed
US-7786159-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2010-08-31 US disclosed
US-7786159-B2 Thrombopoietin mimetics STATEGICS, INC. (US) 2010-08-31 US disclosed
US-20080139621-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2008-06-12 US disclosed
US-20080139621-A1 Thrombopoietin Mimetics STATEGICS, INC. (US) 2008-06-12 US disclosed
WO-2008070583-A2 THROMBOPOIETIN MIMETICS STATEGICS, INC. (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336706-B2 Crystalline form of Eltrombopag free acid ACKR3, PLG, GCG ALDH1A1 4015/4885KMT2A 4148/4885MEN1 780/4885
US-20170275255-A1 CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID ACKR3, PLG, GCG ALDH1A1 4015/4885KMT2A 4148/4885MEN1 780/4885
US-20100256212-A1 POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF THPO, MPL, PTGER1 ALDH1A1 2152/4885KMT2A 3367/4885MEN1 1258/4885
US-20080139621-A1 Thrombopoietin Mimetics MPL, THPO, TEK ALDH1A1 2613/4885KMT2A 2684/4885MEN1 569/4885
US-20100323965-A1 Thrombopoietin Mimetics MPL, THPO, TEK ALDH1A1 2613/4885KMT2A 2684/4885MEN1 569/4885
US-20120238612-A1 POLYMORPHS OF ELTROMBOPAG AND ELTROMBOPAG SALTS AND PROCESSES FOR PREPARATION THEREOF THPO, MPL, PTGER1 ALDH1A1 2152/4885KMT2A 3367/4885MEN1 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.